Increasing transparency of Good Manufacturing Practice (GMP) inspection outcomes

Overview

The Therapeutic Goods Administration (TGA) is seeking feedback on a proposal to publish information about Good Manufacturing Practice (GMP) compliance on the TGA website.

The purpose of publishing this information is to:

  • improve transparency of regulatory oversight of the manufacture of pharmaceutical products supplied in Australia;
  • help the public better understand the safeguards in place to ensure quality of pharmaceutical products; and
  • provide clearer and more accessible regulatory information for industry and other stakeholders.

Why your views matter

The TGA is seeking comment to help inform decisions about the scope, format and presentation of information published on the TGA website.

In particular, the TGA is seeking views on:

  • how GMP certificates and inspection outcomes should be displayed and accessed
  • how to ensure published information is clear, accurate and does not disclose confidential information
  • any potential benefits or impacts of publishing this information.

We want your input

This activity will open on 10 Jun 2026. Please come back on or after this date to give us your views.

Opens 10 Jun 2026

Closes 13 Jul 2026

Contact

1800 020 653

MQB.Coordination@health.gov.au

Audiences

  • Consumer/Public
  • Consumers
  • Health professional
  • Industry
  • Manufacturer
  • Manufacturers
  • Sponsor
  • Sponsors

Interests

  • Compliance and enforcement
  • Labelling and packaging
  • Manufacturing